Companies:

AI screening with AI: OminiAb

complete human antibodies: Infinimmune

Production of Antibody Fragments:

Production of Light chains dimers in E. coli:

Rognoni (“A strategy for synthesis of pathogenic human immunoglobulin free light chainsin E. coli. PLOS One, 8(9), 2013) discloses production of pathogenic human immunoglobulin free light chains in E. coli which includes the steps of cloning free LC cDNA (total RNA was extracted from bone marrow mononuclear cells from amyloidosis patients), construction of an expression vector endoing the recombinant free LC cDNA, followed by expression in inclusion bodies of E. coli. The rLC were isolated form the inclusion bodies, refolded into their bioactive form by a dilution method in the presence of reduced and oxidized glutathione. The refolded recombinant proteins were then purified by anion exchange chomatoraphy. The oligomeric state of the rLC was preformed by size exclusion chromatography. The natural AL-2 BJ protein was also run as control. Each protein eluted form the column as a single main peak. Peaks were at a position of about 40-44 kDa, in agreement with the expected value for the dimeric form of LC. The biochemical characterization idicated that the recombinant proteins exhibited typical properties of immunoglobulin LC, and that the rAL-2 was virtually indistiguishable form relative BJ protein. Moreover, rLC proteins were arranged as dimers in solution a feature evidencing proper folding since it is known that the capability of immunoglboulin LC of forming dimers depends essentially on the correct formation of protein’s secondary structure. 

Production by Yeast surface dispaly (YSD):

In YSD, the protein of interest is expressed as a fusion with a yeast mating protein Aga2p, which is targeted to the yeast cell wall. Once expressed on the yeast surface, protein properties such as stability and affinity can be quntitatively measrued suing fluorescently labeled reagents and fly cytometry. Further, libraries of mutants can be sorted for desired properties using fluorescence activated cell sorting (FACS). Colby (J. Mol. Biol. 2004, 342, 901-912)

Antibody Selection and Production:

Sharma (US 2017/0091377) discloses methods to aid in antibody selection and manufacturing by using structural parmeters which are identified thorugh molecular dynamics simulations which predict desirable attribues of mAbs such as low viscosity, shlf-life and pharmacokinetic behavior. For example, antibody amino acid sequence such as charge and hydrophobicity are sufficient to differentiate between mAbs of varying viscosity-concetnraiton profiles. Each of the physiochemcial characteristics may have a particular design criterion such as a limit, a threshold or a cut-off value. For example, the design cirterion may be a viscosity limit. 

Zhou (US 16/998,3891, published as US 2021/0054050) discloses methods for producing bispecific antibodies which includes determining a profile of protein-protein interactions such as attractive or repulsive interactions of their constituent amino acid sequences and selecting a target profile of the protein-protein interactions and producing a combination of the sequences according to the target profile. The method includes determining a profile of physicochemical proeprties of the peptides such as isoelectric point, viscosity, surface hydrophobicity, dhyrophoicity index.